tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Chad Mabry, 48 are a BUY (97.96%), 1 are a HOLD (2.04%).
Analyst Chad Mabry, currently employed at B. RILEY, carries an average stock price target met ratio of 47.06% that have a potential upside of 33.12% achieved within 269 days. Previously, Chad Mabry worked at JONESTRADING, LADENBURG.
Chad Mabry’s has documented 102 price targets and ratings displayed on 17 stocks. The coverage is on Energy, Healthcare sectors.
Most recent stock forecast was given on ARWR, Arrowhead Pharmaceuticals at 22-Oct-2025.
Analyst best performing recommendations are on NVAX (NOVAVAX).
The best stock recommendation documented was for NVAX (NOVAVAX) at 11/27/2019. The price target of $12 was fulfilled within 93 days with a profit of $8.06 (204.57%) receiving and performance score of 22.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold Since 26-Feb-2024
$38
$2.24 (6.26%)
$40
2 years 7 months 25 days ago
(26-Feb-2024)
4/13 (30.77%)
$7.17 (23.26%)
14
Buy Since 13-Apr-2017
$32
$-3.76 (-10.51%)
$44
2 years 8 months 28 days ago
(23-Jan-2024)
1/10 (10%)
$0.42 (1.33%)
1
Buy Since 09-Mar-2022
$45
$9.24 (25.84%)
$51
2 years 9 months 13 days ago
(08-Jan-2024)
4/18 (22.22%)
$10.47 (30.32%)
9
Hold Since 19-Apr-2023
$40
$4.24 (11.86%)
$41
2 years 10 months 22 days ago
(29-Nov-2023)
1/4 (25%)
$8.43 (26.70%)
45
$40
$4.24 (11.86%)
$41
2 years 10 months 22 days ago
(29-Nov-2023)
3/14 (21.43%)
$8.43 (26.70%)
41
What Year was the first public recommendation made by Chad Mabry?
